OncoMed leverages in-house discovery research, multiple antibody discovery technologies, a comprehensive biomarker and translational
medicine effort, and proven process development and antibody cell line development expertise.
We utilize proprietary technologies to create novel biologics uniquely tailored to achieve specific therapeutic strategies. Among
these technologies is a bispecific antibody technology, exemplified by our navicixizumab program, a potent inhibitor of both VEGF
Another key platform is our TNF trimer Platform. This technology enables the development of robust fully human agonists of the TNF
receptor family of ligands. This technology underlies our GITRL-Fc program, OMP-336B11, and is being leveraged to create additional
novel therapeutics that leverage the fundamental immune functions controlled by various members of the TNF superfamily.
OncoMed’s technology enables the production of bispecific antibodies containing two distinct heavy chains.
Each heavy chain can bind to a distinct target antigen.
Single-gene TNF family Trimers
The TNF family of ligands function as trimeric cytokines. OncoMed's technology leverages the recognition that the N and C
terminus of TNF family monomers are in close proximity within the trimeric cytokine, and can be tethered without use of linker
sequence to create fully human single-gene trimers that are amenable to use in recombinant therapeutic design.